Morgan Stanley’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $27.4M | Buy |
841,922
+234,971
| +39% | +$7.64M | ﹤0.01% | 2495 |
|
|
2025
Q1 | $22.9M | Sell |
606,951
-86,382
| -12% | -$3.26M | ﹤0.01% | 2554 |
|
|
2024
Q4 | $56.8M | Sell |
693,333
-1,536
| -0.2% | -$126K | ﹤0.01% | 1727 |
|
|
2024
Q3 | $79.4M | Buy |
694,869
+285,177
| +70% | +$32.6M | 0.01% | 1415 |
|
|
2024
Q2 | $30.9M | Sell |
409,692
-80,762
| -16% | -$6.1M | ﹤0.01% | 2197 |
|
|
2024
Q1 | $33.5M | Sell |
490,454
-584,276
| -54% | -$39.9M | ﹤0.01% | 2140 |
|
|
2023
Q4 | $67.5M | Buy |
1,074,730
+665,180
| +162% | +$41.8M | ﹤0.01% | 2132 |
|
|
2023
Q3 | $20.9M | Sell |
409,550
-15,540
| -4% | -$792K | ﹤0.01% | 2410 |
|
|
2023
Q2 | $21.2M | Buy |
425,090
+254,467
| +149% | +$12.7M | ﹤0.01% | 2415 |
|
|
2023
Q1 | $6.39M | Buy |
170,623
+2,508
| +1% | +$94K | ﹤0.01% | 3563 |
|
|
2022
Q4 | $8.06M | Buy |
168,115
+125,582
| +295% | +$6.02M | ﹤0.01% | 3283 |
|
|
2022
Q3 | $1.02M | Sell |
42,533
-95,138
| -69% | -$2.28M | ﹤0.01% | 4865 |
|
|
2022
Q2 | $3M | Buy |
137,671
+48,740
| +55% | +$1.06M | ﹤0.01% | 4212 |
|
|
2022
Q1 | $2.15M | Buy |
88,931
+31,088
| +54% | +$751K | ﹤0.01% | 4470 |
|
|
2021
Q4 | $1.38M | Buy |
57,843
+19,767
| +52% | +$470K | ﹤0.01% | 4857 |
|
|
2021
Q3 | $966K | Buy |
38,076
+18,200
| +92% | +$462K | ﹤0.01% | 5063 |
|
|
2021
Q2 | $449K | Buy |
19,876
+10,405
| +110% | +$235K | ﹤0.01% | 5595 |
|
|
2021
Q1 | $187K | Sell |
9,471
-4,088
| -30% | -$80.7K | ﹤0.01% | 5693 |
|
|
2020
Q4 | $360K | Buy |
13,559
+10,600
| +358% | +$281K | ﹤0.01% | 5263 |
|
|
2020
Q3 | $146K | Buy |
2,959
+2,859
| +2,859% | +$141K | ﹤0.01% | 5259 |
|
|
2020
Q2 | $3K | Buy |
+100
| New | +$3K | ﹤0.01% | 6399 |
|